MSD's stock price rose 3% as its partner Collumbott announced positive results in Coruida's key lung cancer research.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.